Ridgeback Capital — 2015 Investments

2 investments dated 2015 · listed companies and verified rows first · show all

Freenomefreenome.com in 𝕏NASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRA Capital Agent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company +15 more

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)in John Leonard(President and Chief Executive Officer)in James Basta(Executive Vice President, General Counsel and Corporate Secretary)in Edward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsage1 Atlas Venture Avoro Capital Advisors EcoR1 Capital Foresite Capital OrbiMed +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.